TrialNature medicine2026

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Omar Nadeem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.